All times are listed in CEST (Central European Summer Time)

PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Post-session Questions (ID 271)

YO “HowTo” Session: How to move genomic profiling to clinical practice by multidisciplinary collaboration? (ID 3)

Closing remarks (ID 20)

Gilead - Triple-Negative Breast Cancer: See Beyond the Negatives (ID 35)

Live Q&A (ID 411)

Lecture Time
11:30 - 11:30
Room
Munich Hall
Date
Tue, 03.05.2022
Time
11:30 - 12:30
AstraZeneca - Controversies in Breast Cancer (ID 48)

Treatment beyond CDK4/6i - what comes next? (ID 471)

Lecture Time
12:00 - 12:15
Room
Cologne Hall
Date
Tue, 03.05.2022
Time
11:30 - 12:30
PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Conclusions (ID 272)

PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Introduction (ID 267)

AstraZeneca - Controversies in Breast Cancer (ID 48)

Q&A / discussion (ID 478)

Lecture Time
12:15 - 12:30
Room
Cologne Hall
Date
Tue, 03.05.2022
Time
11:30 - 12:30
PER-sponsored supported by Sanofi Genzyme - Tumor Board: How the Experts Approach Personalized Care Plans in ER+ BC (ID 5)

Tumor Board 1: Current Management Options for HR+/HER2- Metastatic Breast Cancer (ID 268)

Gilead - Triple-Negative Breast Cancer: See Beyond the Negatives (ID 35)

Welcome and introduction (ID 408)

Lecture Time
11:30 - 11:30
Room
Munich Hall
Date
Tue, 03.05.2022
Time
11:30 - 12:30
Welcome to the ESMO Breast Cancer 2022 and 2022 Award lecture (ID 24)

Introduction to the ESMO Breast Cancer 2022 Award lecture (ID 480)

Lecture Time
13:10 - 13:15
Room
Berlin Hall
Date
Tue, 03.05.2022
Time
13:00 - 13:40
Welcome to the ESMO Breast Cancer 2022 and 2022 Award lecture (ID 24)

What we have learned from neoadjuvant therapy, and what not (ID 481)

Lecture Time
13:15 - 13:40
Room
Berlin Hall
Date
Tue, 03.05.2022
Time
13:00 - 13:40
Welcome to the ESMO Breast Cancer 2022 and 2022 Award lecture (ID 24)

Welcome to the ESMO Breast Cancer 2022 (ID 479)